Nebulised pentamidine prophylaxis of pneumocystis pneumonia in adults accessing HIV services at royal free hospital, London
International Journal of STD & AIDS · 2024
DOI: 10.1177/09564624241245155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of STD & AIDS, 2024. Verfasst von Malin Bergstrom und 7 weiteren Autor:innen. Beteiligte Einrichtung: HIV Services, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK. Hauptthemen laut MEDLINE: Pentamidine, Pneumonia, Pneumocystis, HIV Infections, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Receipt of nebulised pentamidine in people with HIV was audited to identify if individuals were appropriately receiving nebulised pentamidine, and whether national guidelines were being followed when prophylaxis was commenced and discontinued. Of 76 people with who received nebulised pentamidine, the main indication for starting nebulised pentamidine was a co-trimoxazole adverse drug reaction. Co-trimoxazole desensitization was not attempted before starting nebulised pentamidine. The main indication for stopping nebulised pentamidine prophylaxis was when immune reconstitution occurred. This single centre audit revealed that national guidelines were being followed in most cases. The lack of information regarding the reason for starting or stopping nebulised pentamidine prophylaxis, or detail of the clinician’s concerns about potential poor adherence with oral regimens of prophylaxis as a reason for choosing nebulised pentamidine prophylaxis, identifies a need for improved documentation of clinicians’ decision-making. Introduction of pharmacist-led interventions/alerts using patients’ electronic records, similar to those used in primary care, would enable the specialist pharmacy team to identify when and if co-trimoxazole desensitization has been offered and discussed/declined before a clinician prescribes nebulised pentamidine as well as enabling identification of those in who pentamidine prophylaxis has been continued, despite “immune reconstitution”.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Services, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
- Pharmacy Services, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
- Medicine and Urgent Care, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
- UCL Respiratory, Division of Medicine, University College London, London, UK.
- Respiratory Medicine, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
- Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.
ORCID-Profile: Robert F Miller
Zitieren
APA
Bergstrom, M., Rahim, A., Akodu, J., Marshall, G., Harrison, C., Penrose, L., Lipman, M. C., & Miller, R. F. (2024). Nebulised pentamidine prophylaxis of pneumocystis pneumonia in adults accessing HIV services at royal free hospital, London. International Journal of STD & AIDS. https://doi.org/10.1177/09564624241245155
Vancouver
Bergstrom M, Rahim A, Akodu J, Marshall G, Harrison C, Penrose L, et al. Nebulised pentamidine prophylaxis of pneumocystis pneumonia in adults accessing HIV services at royal free hospital, London. International Journal of STD & AIDS. 2024. doi:10.1177/09564624241245155
BibTeX
@article{Bergstrom2024,
author = {Bergstrom, Malin and Rahim, Anika and Akodu, Jane and Marshall, Gavin and Harrison, Cora and Penrose, Louisa and Lipman, Marc Ci and Miller, Robert F},
title = {Nebulised pentamidine prophylaxis of pneumocystis pneumonia in adults accessing HIV services at royal free hospital, London},
journal = {International Journal of STD & AIDS},
year = {2024},
doi = {10.1177/09564624241245155}
}
EUVIMED